2027 Leads Physicians 
European Pharmaceutical Review
FEBRUARY 8, 2023
It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.
PM360
SEPTEMBER 21, 2023
CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
APRIL 24, 2023
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006.
Medico Reach
DECEMBER 2, 2022
billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Moreover, its services are spread through care organizations, hospitals, government agencies, pharmaceutical companies, and physicians. In 2022, the global clinical research market stands at $63.6 billion with a CAGR of 11.0%
Medico Reach
SEPTEMBER 19, 2022
Almost 44% of physicians forecast telehealth use to attend to half of their appointments. As you can observe, 65% of physicians did not use telehealth in the pre-pandemic era. Remote patient monitoring technology leads to effective treatment of lifestyle disorders. Benefits of Telehealth. Enhanced Patient Outcomes.
European Pharmaceutical Review
MARCH 4, 2024
percent through 2027. These actions occur at both the delivery site and other systemic locations, thereby promoting an immunogenic response that leads to cancer cell death. Dave Li, PhD Dave Li is a principal consultant and Clinical Research Physician with KCR.
Pharmaceutical Technology
JANUARY 10, 2023
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
Expert insights. Personalized for you.
98 
Let's personalize your content